Olema Pharmaceuticals, Inc. (OLMA)
Free
No email, no account, no signup.
Pulling latest news for Olema Pharmaceuticals, Inc.…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report –
Order analysis – $4.99 $1.25
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Targeted therapies for women's cancers
Market Cap
$862M
We're already tracking Olema Pharmaceuticals, Inc. — here are the latest events we've registered
Recent News
- In May 2026, Olema announced a clinical trial collaboration with Bayer to evaluate its KAT6 inhibitor, OP-3136, in combination with darolutamide for metastatic prostate cancer. The company also presented encouraging initial Phase 1 data for OP-3136 at the 2026 ASCO Annual Meeting, demonstrating anti-tumor activity across multiple solid tumor types. Top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant is anticipated in the fall of 2026.
Want to know how this news affects Olema Pharmaceuticals, Inc.? Order the analysis.
Order analysis – What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Sources: news, filings, market data, and investor forums
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Olema Pharmaceuticals, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.